JP2024524288A - アデノシン三リン酸（ａｔｐ）を含む組成物および認知機能に対する使用方法 - Google Patents

アデノシン三リン酸（ａｔｐ）を含む組成物および認知機能に対する使用方法 Download PDF

Info

Publication number
JP2024524288A
JP2024524288A JP2023579443A JP2023579443A JP2024524288A JP 2024524288 A JP2024524288 A JP 2024524288A JP 2023579443 A JP2023579443 A JP 2023579443A JP 2023579443 A JP2023579443 A JP 2023579443A JP 2024524288 A JP2024524288 A JP 2024524288A
Authority
JP
Japan
Prior art keywords
atp
composition
administered
per day
person
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524288A5 (https=
Inventor
ラスメイチャー、ジョン
コルブ、ラリー
ベイヤー、ショーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsi Usa LLC
Original Assignee
Tsi Usa LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Usa LLC filed Critical Tsi Usa LLC
Publication of JP2024524288A publication Critical patent/JP2024524288A/ja
Publication of JP2024524288A5 publication Critical patent/JP2024524288A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2023579443A 2021-06-22 2022-06-22 アデノシン三リン酸（ａｔｐ）を含む組成物および認知機能に対する使用方法 Pending JP2024524288A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213378P 2021-06-22 2021-06-22
US63/213,378 2021-06-22
PCT/US2022/034510 WO2022271813A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Publications (2)

Publication Number Publication Date
JP2024524288A true JP2024524288A (ja) 2024-07-05
JP2024524288A5 JP2024524288A5 (https=) 2025-06-30

Family

ID=84544774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579443A Pending JP2024524288A (ja) 2021-06-22 2022-06-22 アデノシン三リン酸（ａｔｐ）を含む組成物および認知機能に対する使用方法

Country Status (12)

Country Link
US (1) US20240299435A1 (https=)
EP (1) EP4358972A4 (https=)
JP (1) JP2024524288A (https=)
CN (1) CN117835985A (https=)
AU (1) AU2022297444A1 (https=)
CA (1) CA3224861A1 (https=)
CL (1) CL2023003882A1 (https=)
CO (1) CO2024000517A2 (https=)
EC (1) ECSP24004256A (https=)
MX (1) MX2024000145A (https=)
PE (1) PE20241617A1 (https=)
WO (1) WO2022271813A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
WO2008001494A1 (en) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients
PH12022550598A1 (en) * 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
US20140044690A1 (en) * 2012-08-08 2014-02-13 University Of South Florida High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
US10092590B2 (en) * 2012-09-10 2018-10-09 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2014106860A2 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
BR112022004108A2 (pt) * 2019-09-05 2022-05-31 Tsi Group Ltd Métodos para aprimorar a absorção gastrointestinal e utilização sistêmica de materiais nutricionais, para aumentar a biodisponibilidade de um material nutricional em um animal e para aprimorar a absorção de um material nutricional em ser humano

Also Published As

Publication number Publication date
CN117835985A (zh) 2024-04-05
PE20241617A1 (es) 2024-08-07
WO2022271813A1 (en) 2022-12-29
EP4358972A4 (en) 2025-04-16
CA3224861A1 (en) 2022-12-29
CO2024000517A2 (es) 2024-05-10
AU2022297444A1 (en) 2024-01-18
CL2023003882A1 (es) 2024-07-05
MX2024000145A (es) 2024-03-22
EP4358972A1 (en) 2024-05-01
ECSP24004256A (es) 2024-02-29
US20240299435A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
Antonio et al. Effects of exercise training and amino-acid supplementation on body composition and physical performance in untrained women
Hoffman et al. Effect of nutritionally enriched coffee consumption on aerobic and anaerobicexercise performance
US9907331B2 (en) Rice protein supplement and methods of use thereof
US20170318852A1 (en) Rice protein supplement and methods of use thereof
Fukuda et al. The possible combinatory effects of acute consumption of caffeine, creatine, and amino acids on the improvement of anaerobic running performance in humans
US20020035069A1 (en) Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans
Sunderland et al. VO^ sub 2^ MAX AND VENTILATORY THRESHOLD OF TRAINED CYCLISTS ARE NOT AFFECTED BY 28-DAY L-ARGININE SUPPLEMENTATION
RU2468609C1 (ru) Продукт белково-витаминный для питания спортсменов
Wismanadi et al. Glutamine accelerates post-exercise recovery of arms power, leg power, and smash velocity at 48 hours for non-elite badminton athletes
JP2024524288A (ja) アデノシン三リン酸（ａｔｐ）を含む組成物および認知機能に対する使用方法
Zahabi et al. The Effect of Whey Protein and Creatine Supplementation on the Physical Fitness‎ Indicators, Velocity and Muscle Hypertrophy of Untrained Women during a Resistance-‎ Training Period
Wax et al. Acute ingestion of L-arginine alpha-ketoglutarate fails to improve muscular strength and endurance in ROTC cadets
Syrotuik et al. Effect of elk velvet antler supplementation on the hormonal response to acute and chronic exercise in male and female rowers
Hakimi et al. The effects of glutamine supplementation on performance and hormonal responses in non-athlete male students during eight week resistance training
Hara et al. Effects of pycnogenol-containing supplement on professional cycling performance: a single-group pretest-posttest pilot study
WO2021239823A1 (en) Preventing or treating nitric oxide deficiency related conditions
US10888576B2 (en) Composition of HMB and ATP and methods of use
RU2848641C1 (ru) Способ повышения общей физической работоспособности спортсменов, специализирующихся в игровых видах спорта
Amin et al. The effect of glutamine and glucose supplementation on maximal aerobic power and hemoglobin concentration in athlete young girls
Sakong Effect of beetroot juice supplementation on aerobic and anaerobic capacities, and isokinetic muscle functions in power athletes
Daraei et al. L-Arginine Improves Endurance to High-Intensity Interval Exercises in Overweight Men
Gouttebarge et al. Short-term oral creatine supplementation in professional football players: a randomized placebo-controlled trial
Smolka et al. Caffeine intake enhances endurance performance in sub-elite but not in elite athletes
Soliman Elsharkawy et al. The Impact of a Training Program for Development Strength Endurance with Taking L-Arginine on Body Composition and 5000m Running Records
Sadeghi et al. Short-term effects of glutamine supplementation on levels of blood lactate and fatigue index in male elite swimmers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250620